Clinical Application of Cytokines in Cancer Immunotherapy
Yi Qiu,Mengxi Su,Leyi Liu,Yiqi Tang,Yuan Pan,Jianbo Sun
DOI: https://doi.org/10.2147/DDDT.S308578
2021-05-27
Abstract:Yi Qiu, 1– 3 Mengxi Su, 1, 3 Leyi Liu, 1, 3 Yiqi Tang, 1, 3 Yuan Pan, 1, 3 Jianbo Sun 1, 3 1 Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-Sen University, Guangzhou, People's Republic of China; 2 Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, People's Republic of China; 3 Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, People's Republic of China Correspondence: Jianbo Sun Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-Sen University, No. 74, Zhongshan Er Road, Guangzhou, Guangdong, 510080, People's Republic of China Tel +86-20-87330589 Email Cytokines are key components of the immune system and play pivotal roles in anticancer immune response. Cytokines as either therapeutic agents or targets hold clinical promise for cancer precise treatment. Here, we provide an overview of the various roles of cytokines in the cancer immunity cycle, with a particular focus on the clinical researches of cytokine-based drugs in cancer therapy. We review 27 cytokines in 2630 cancer clinical trials registered with ClinicalTrials.gov that had completed recruitment up to January 2021 while summarizing important cases for each cytokine. We also discuss recent progress in methods for improving the delivery efficiency, stability, biocompatibility, and availability of cytokines in therapeutic applications. Keywords: cytokine therapy, cancer immunity cycle, cancer immunotherapy, clinical trial, nanomedicine Cancer is a disease characterized by the abnormalities in the regulation of cell proliferation and differentiation. Many factors contribute to cancer development including genetics, 1 lifestyle, and environmental carcinogens, among others. 2 Cancer is the second leading cause of death worldwide after cardiovascular disease, accounting for 9.6 million deaths in 2018 according to data from the International Agency for Research on Cancer. Lung cancer is the leading cause of cancer death (18.4%), followed by breast cancer (11.6%), and prostate cancer (7.1%). 3 Clinical manifestations include pain, bleeding, lumps and ulcers at the site of disease, along with systemic symptoms such as weight loss and fatigue leading to cachexia. Traditional treatment modalities including surgery, radiotherapy, and chemotherapy have various disadvantages and cause side effects that are in some cases severe. Immunotherapies such as blockade of programmed death (PD)-1 and programmed death ligand 1 (PD-L1) immune checkpoints; chimeric antigen receptor T cell immunotherapy (CAR-T); using the monoclonal antibody against cancer antigen; and cytokine therapy offer a promising alternative to the conventional treatment approaches for cancer. 4 In particular, cytokine therapy has shown encouraging results in both basic and clinical research settings. 5 Cytokines are small proteins produced by various cells (immunocytes and non-immunocytes) as molecular messengers to communicate with each other or with other cells. Cytokines have versatile roles in several steps of the cancer immunity cycle including cancer antigen presentation, T cell priming and activation, effector T cell infiltration in cancer site, and cancer cell death, as shown in Figure 1 . More importantly, cytokine-mediated signaling pathways control the direction of naïve CD4 + T cell differentiation and thus determine the effects of anticancer immunity ( Figure 2 and Table 1 ). Briefly, transforming growth factor β (TGF-β) signaling in naïve CD4 + T cells is required for the differentiation of regulatory T cells (Tregs) and T helper type 17 (Th17) cells, both of which promote tumor progression. Additionally, Th17 cell differentiation and clonal expansion require a cocktail of cytokines (IL-6, IL-21, IL-23, IL-1β, and TGF-β). 6–10 IL-17 secreted by Th17 cells guides macrophages and neutrophils to cancer sites and induces cancer-promoting inflammation. Th17 cells themselves also exert antitumor effects in the melanoma microenvironment by potentiating the functions of CD8 + T cells and T helper type 1 cells (Th1 cells). 11 IL-10, IL-11, IL-4, and IL-13 are critical for the differentiation and development of T helper type 2 cells (Th2 cells), 12–17 whereas IL-12, IL-18, IL-1β, and interferon (IFN)-γ promote Th1 cell development and activity. <a -Abstract Truncated-